WW International (WW) Earnings Date & Reports

Key Takeaways

• WW International is scheduled to report Q2 2026 results after market close on Wednesday, August 5, 2026.
• Wall Street consensus expects quarterly revenue near $159 million, down from $189 million in the year-ago quarter, reflecting ongoing subscriber migration trends.
• Analysts project adjusted EPS of approximately $0.48, though estimates range widely, highlighting deep uncertainty around the pace of the company's clinical transformation.
• Investors will focus on clinical subscriber growth, ARPU (Average Revenue Per User) trends, and progress toward the company's full-year guidance of $620 million to $635 million in revenue.
• The stock enters earnings near $14, down roughly 69% from its 52-week high, as the market weighs the promise of the GLP-1 strategy against persistent behavioral subscriber declines.

Earnings Context and Why It Matters

WW International, known to consumers as Weight Watchers, is navigating one of the most consequential transformations in its six-decade history. The company is repositioning itself from a traditional behavioral weight-management brand into an integrated platform that combines GLP-1 medications with clinical support, community tools, and behavioral coaching. This strategy has shown early traction — Q1 2026 clinical subscribers surged 51% sequentially to 197,000 — but has come at the cost of declining behavioral subscribers and compressed GAAP (Generally Accepted Accounting Principles) profitability. With the stock trading near the lower end of its 52-week range and activist pressure mounting, the Q2 report represents a critical checkpoint for the turnaround narrative.

Earnings Expectations

Consensus estimates for WW's second quarter, which ended June 30, 2026, point to revenue of approximately $159 million, according to data from multiple analyst aggregators. This would represent a meaningful decline from the $189 million reported in Q2 2025, consistent with the company's ongoing shift in subscriber composition — trading lower-ARPU behavioral members for higher-ARPU clinical and Core+ subscribers. Adjusted EPS consensus sits near $0.48, though individual estimates span a wide spectrum from $0.24 to $0.82, underscoring the difficulty analysts face in modeling the pace and margin impact of the clinical ramp.

The company enters the quarter with reaffirmed full-year guidance calling for revenue of $620 million to $635 million and adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $105 million to $115 million. Management has also signaled that 2026 will be a cash-flow-positive year. Key metrics to watch include clinical subscriber net additions — management has cautioned that Q2 net adds should moderate from Q1's torrid pace — as well as ARPU, which rose 13% year-over-year to $20.59 in Q1. The Core+ tier, which grew 6% to 537,000 subscribers last quarter, will also be scrutinized as evidence that the behavioral side of the business can stabilize.

AI Screener

As WW International approaches its Q2 earnings release, investors seeking to identify timely opportunities across the broader market may benefit from tools designed to streamline the research process. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. Rather than manually scanning markets, users can surface trade ideas, breakout candidates, and trending stocks with greater speed and precision. For those looking to complement their earnings-season research with data-driven screening, the AI Screener offers a practical starting point.

Market Reaction and Investor Sentiment

Sentiment heading into WW's Q2 report is cautious but not uniformly bearish. The stock has stabilized in the $13 to $16 range in recent weeks, well above its 52-week low of $8.37 but far below the $45 peak. Analyst coverage remains thin — roughly three firms actively publish on the name — with consensus tilting toward Hold. Price targets range from $20 to $35, implying significant upside if execution improves. However, the Q1 report offers a cautionary template: revenue beat expectations, but a large GAAP EPS miss and ongoing behavioral subscriber erosion triggered volatility. Key risks include whether clinical growth can sustainably offset legacy declines, how gross margins hold up as clinical services scale, and whether the recent CEO vacancy — currently managed by an interim office of the CEO — creates execution uncertainty. The addition of three new independent directors and an activist letter from Galloway Capital Partners have added a layer of corporate governance dynamics that investors will be monitoring closely.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, several strategic developments will shape the investment narrative for WW in the second half of 2026 and into 2027.

The launch of the Medicare GLP-1 Bridge Program on July 1, 2026, which offers eligible Part D members access to certain GLP-1 medications for $50 per month alongside clinical and behavioral support through the Med+ platform, represents a potentially significant growth catalyst. Early enrollment data and any commentary on the ramp of this program will be closely watched, as it could meaningfully expand the addressable market for WW's clinical services.

On the cost side, management has outlined a plan to deploy $37 million in cash during Q2 to reduce its term loan principal by $42 million through a voluntary tender offer at 68.5% of face value. At the loan's 10.5% interest rate, this transaction is expected to generate approximately $4 million in annual interest savings, improving the path to sustained free cash flow generation. Investors should also monitor marketing spend efficiency — Q1 saw elevated marketing investment of $93 million tied to the Wegovy oral launch — and whether that spending translates into durable subscriber acquisition.

The structural shift toward clinical and Core+ subscriptions continues to reshape WW's financial profile. Clinical revenue grew 32% year-over-year in Q1 and is expected to reach 25% to 30% of total revenue in 2026, up from 16% in 2025. While this transition pressures near-term top-line comparisons due to the higher churn and lower volume of behavioral subscriptions, the long-term thesis hinges on whether higher ARPU and improved member lifetime value can drive a return to sustainable revenue growth. With the stock priced for skepticism, the August 5 report will offer the next major data point in that debate.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations